CORONA, Calif., April 15 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that the United States District Court for the District of Arizona has entered an order vacating the Consent Decree of Condemnation and Permanent Injunction previously entered against Steris Laboratories, Inc. (Steris) on October 21, 1998. The court entered the order vacating the consent decree upon Steris' request, which the United States Food and Drug Administration (FDA) agreed not to oppose.
In September 2003, the independent expert consulting group engaged by Steris completed its final inspection of the Steris manufacturing facility required under the terms of the 1998 consent decree. The inspection found the facility to be in a satisfactory state of good manufacturing practices control. In March 2004, FDA inspected the Steris facility and reported no objectionable conditions.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.
For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watsonpharm.com/.
Forward-Looking Statement Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, successful compliance with governmental regulations, the FDA's agreement with the findings of the independent expert inspection, and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2003.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comWatson Pharmaceuticals, Inc.CONTACT: investors , Patty Eisenhaur, +1-909-493-5611, or media, ChrisEso, +1-909-493-4013, both of Watson Pharmaceuticals, Inc.
Web site: http://www.watsonpharm.com/
